US · CHEK
Check-Cap Ltd.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Isfiya 30090
- Website
- check-cap.com
Price · as of 2024-12-31
—
Market cap 7.9M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $1,452.00 | ||||
| 2015 | $720.00 | $3,140.81 | $16.56 | $0.00 | |
| 2016 | $523.20 | $1,422.45 | $47.38 | $0.00 | $0.00 |
| 2017 | $168.00 | $76.36 | |||
| 2018 | $42.80 | ||||
| 2019 | $28.20 | ||||
| 2020 | $30.60 | ||||
| 2021 | $7.94 | ||||
| 2022 | $2.98 | ||||
| 2023 | $1.93 | ||||
| 2024 | $0.80 |
AI valuation
Our deep-learning model estimates Check-Cap Ltd.'s (CHEK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CHEK | Check-Cap Ltd. | $1.35 | 7.9M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| ACXP | Acurx Pharmaceuticals, In… | $5.15 | 8.16M | — | — | — | — | -0.55 | 12.65 | — | — | — | 12.65 | 0.00% | — | — | -534.03% | 478.14% | -243.85% | 0.00 | — | 1.19 | 1.16 | — | -2355.00% | — | 594.00% | -133.41% | -3.20 | 352.03% | 0.00% | 0.00% | 0.00% | -0.29 | -0.39 | — | -34.86 |
| ADIL | Adial Pharmaceuticals, In… | $0.33 | 7.26M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| BFRI | Biofrontera Inc. | $1.09 | 11.63M | +13,983% | -66% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| HCWB | HCW Biologics Inc. | $3.31 | 7.12M | +913% | +76% | — | -75% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| LUCY | Innovative Eyewear, Inc. | $1.58 | 7.23M | +1,568% | +28,515,951% | — | — | -0.81 | 0.69 | 3.84 | 0.16 | — | 0.73 | 13.15% | -484.20% | -474.60% | -106.00% | -557.55% | -96.74% | 0.00 | — | 12.52 | 10.38 | 0.35 | -5904.00% | 4199.00% | 1643.00% | -111.49% | -9.14 | -493.01% | 0.00% | 0.00% | 0.00% | 0.16 | 0.18 | -0.76 | 0.10 |
| MYNZ | Mainz Biomed B.V. | $1.42 | 5.81M | +15,965% | +58% | — | — | -0.25 | 0.90 | 6.08 | -0.13 | -0.02 | 1.79 | 64.31% | -2091.23% | -2421.80% | -465.82% | -559.63% | -151.15% | 0.54 | -17.39 | 1.32 | 1.08 | 0.15 | 128025.00% | -17.00% | -2724.00% | -319.32% | -2.87 | -519.21% | 0.00% | 0.00% | 61.01% | -0.13 | -0.14 | 2.76 | -13.59 |
| NRSN | NeuroSense Therapeutics L… | $1.05 | 25.87M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| PFSA | Profusa, Inc. Common Stoc… | $0.19 | 7.86M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 8.05% | 6.39% | -371.73% | -0.40 | -1.02 | 0.00 | 0.00 | -9.99 | -968.00% | — | -5309.00% | — | -0.04 | 2.93% | — | 0.00% | — | — | — | — | — |
| SBFM | Sunshine Biopharma, Inc. | $1.77 | 8.06M | +2,910% | +44,030,507% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
About Check-Cap Ltd.
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
- CEO
- Yoav Kimchy
- Employees
- 85
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).